Novocure

Novocure may have finally found a bottom earlier this year. Since April the stock has doubled and it's starting to look like there's a lot more room to go even higher. Novocure has developed a fourth method of treating cancers that can augment or replace surgery, radiation therapy and chemotherapy. The idea of tumor treating fields may one day be the primary method of treating cancers until a cure for cancer can be found. 

This could be one of the most important medical devices ever created for the treatment of cancers and could be in wide use in the next few years. And if that's true, I'd like to be one of their shareholders. Therefore I'll be starting a small position in this company and see where it goes. 

​NovoCure Limited engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) for the treatment of solid tumors. The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, Germany, Switzerland, Japan, and other countries. NovoCure Limited was founded in 2000 and is based in Saint Helier, the Channel Islands.
(Summary) (Company) (Chart)

19 June 2017
Price $15.80
1yr Target $20.40
Analysts 5
Dividend $0.00
Payout Ratio ---

1yr Cap Gain 29.11%
Yield 0.00%
1yr Tot Return 29.11%

P/E ---
PEG ---
Beta ---
​

EPS (ttm) $-1.33
EPS next yr $-0.26
Forward P/E ---
EPS next 5yr 60.00%
1yr Price Support $---

Market Cap $1.40 Bil
Revenues $104.70 Mil
Earnings $-114.50 Mil
Profit Margin ---

Quick Ratio 6.80
Current Ratio 7.60
Debt/Equity 0.75

1yr RevGR 288.48%
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -42.10%
ROE -74.30%

Novocure Revenue Growth

Novocure Weekly Chart

​In 2000, Yoram Palti, founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.
He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.

Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that low-intensity, alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This innovative treatment,   Tumor Treating Fields, or TTFields, is a completely different approach to cancer therapy.

Optune was launched (their TTFields delivery system for glioblastoma) in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, the Company received FDA approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide.  

The science of TTFields has the potential to extend beyond GBM. The Company has five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. They presented their phase 2 pilot data in pancreatic and ovarian cancers at their research and development day on Dec. 12, 2016. In 2016, they began their phase 3 pivotal trial in brain metastases originating from non-small cell lung cancer. Internationally, more than 20 institutions are studying the effects of TTFields in cancer treatment.

The company began with a patient-forward approach that continues to drive their mission today. With more than 15 years of research and many significant milestones, they have established themselves as an innovator in oncology dedicated to improving the lives of cancer patients.
​